BioSpace News Archive

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and Sagimet Biosciences Inc. jointly announced today that they have completed patient enrollment in the ASC40 (TVB-2640) Phase 2 NASH trial in China.

MilliporeSigma today launched its Bio4C™ Orchestrator Software, which allows users to monitor multiple unit operations remotely from a centralized dashboard

Minimally Invasive Endobronchial Valve COPD Treatment with the Spiration® Valve System Now Available to Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma, and Texas

Bayer Fund, a philanthropic arm of life sciences company Bayer, today awarded $3.9 million in grants to 80 charities and non-profit organizations throughout the United States, $300,000 of which is dedicated to supporting initiatives related to COVID-19. Each grant will go toward a program that contributes to one or more of Bayer Fund’s

Vivera Pharmaceuticals is excited to announce a distribution partnership with EcoGroup USA for Vivera’s BioZone, an advanced access control device intended for sanitization in high occupancy settings. BioZone is designed to combine facial recognition, integrated biometrics, and a hospital grade FDA and EPA approved organi

As previously announced, during April 2020, Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga”) and Aegea Biotechnologies, Inc. (“Aegea”) have entered into a collaboration agreement to develop COVID-19 (novel coronavirus) assays.

The Allen Institute announced six new Next Generation Leaders, members of a unique neuroscience advisory panel made up of early-career researchers.

Evommune, Inc., an innovation engine in chronic inflammation, announced the successful completion of a $12.5 million seed financing by Pivotal bioVenture Partners.

OpSens Inc. has been recognized in Deloitte’s 2020 Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America.

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat multi-drug resistant bacterial infectious diseases, today announced clearance by the U.S. Food and Drug Administration (FDA) of the company’s Expanded Access IND for PhageBank™ treatment for pneumonia or bacteremia/septicemia due to Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus in COVID-19 patients.